Identification of predictive factors for early relapse in patients with unresectable stage III NSCLC receiving consolidation durvalumab after concurrent chemoradiation

被引：0
|
作者：
Yeo, Chang Dong
Kang, Hye Seon
Kim, In Kyoung
Lee, Sang Haak
Kim, Jin Woo
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-6757
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6757
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Identification of predictive factors for early relapse in patients with unresectable stage III NSCLC receiving consolidation durvalumab after concurrent chemoradiation
    Nam, Jung Hyun
    Yeo, Chang Dong
    Park, Chan Kwon
    Kim, Sung Kyoung
    Kim, Ju Sang
    Kim, Yong Hyun
    Kim, Jin Woo
    Kim, Seung Joon
    Lee, Sang Hak
    Kang, Hye Seon
    RESPIROLOGY, 2023, 28 : 98 - 98
  • [2] Identification of predictive factors for early relapse in patients with unresectable stage. NSCLC receiving consolidation durvalumab after concurrent chemoradiation therapy
    Nam, Jung Hyun
    Yeo, Chang Dong
    Park, Chan Kwon
    Kim, Sung Kyoung
    Kim, Ju Sang
    Kim, Yong Hyun
    Kim, Jin Woo
    Kim, Seung Joon
    Lee, Sang Haak
    Kang, Hye Seon
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [3] Identification of predictive factors for early relapse in patients with unresectable stage III non-small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy
    Nam, Jung Hyun
    Yeo, Chang Dong
    Park, Chan Kwon
    Kim, Sung Kyoung
    Kim, Ju Sang
    Kim, Yong Hyun
    Kim, Jin Woo
    Kim, Seung Joon
    Lee, Sang Haak
    Kang, Hye Seon
    THORACIC CANCER, 2023, 14 (26) : 2657 - 2664
  • [4] Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
    Lau, Sally C. M.
    Ryan, Malcolm
    Weiss, Jessica
    Fares, Aline Fusco
    Garcia, Miguel
    Schmid, Sabine
    Kuang, Shelley
    Kelly, Deirdre
    Tsao, Ming Sound
    Bradbury, Penelope A.
    Cho, Byoung Chun J.
    Sun, Alexander
    Raman, Srinivas
    Hope, Andrew
    Giuliani, Meredith
    Lok, Benjamin H.
    Bezjak, Andrea
    Liu, Geoffrey
    Leighl, Natasha B.
    Shepherd, Frances A.
    Sacher, Adrian G.
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (12):
  • [5] Evaluating Risk Factors for Pneumonitis in Stage III NSCLC Patients Receiving Durvalumab after Definitive Chemoradiation
    Mo, X.
    Dong, L.
    Patel, S.
    DiCostanzo, D.
    Alahmadi, A.
    Kaufman, J.
    Memmott, R.
    He, K.
    Bertino, E.
    Presley, C.
    Shields, P.
    Otterson, G.
    Carbone, D. P.
    Welliver, M. X.
    Owen, D. H.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S389 - S389
  • [6] Consolidation Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation for Patients with Unresectable Stage III NSCLC
    Durm, G. A.
    Mamdani, H.
    Althouse, S.
    Jabbour, S.
    Ganti, A.
    Jalal, S.
    Chesney, J.
    Naidoo, J.
    Hrinczenko, B.
    Fidler, M. J.
    Leal, T.
    Feldman, L.
    Fujioka, N.
    Hanna, N.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S64 - S64
  • [7] Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
    Vansteenkiste, Johan F.
    Naidoo, Jarushka
    Faivre-Finn, Corinne
    Ozguroglu, Mustafa
    Villegas, Augusto
    Daniel, Davey
    Murakami, Shuji
    Hui, Rina
    Lee, Ki Hyeong
    Cho, Byoung Chul
    Kubota, Kaoru
    Broadhurst, Helen
    Wadsworth, Catherine
    Newton, Michael
    Thiyagarajah, Piruntha
    Antonia, Scott J.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (03):
  • [8] Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation
    Patel, S.
    Zhao, S.
    Wei, L.
    Li, M.
    Bertino, E.
    Presley, C.
    Welliver, M.
    Haglund, K.
    Palmer, J.
    Arnett, A.
    Beyer, S.
    Mende, E.
    Elder, J.
    Hardesty, D.
    Shields, P.
    Carbone, D.
    Otterson, G.
    Williams, T.
    Owen, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S363 - S364
  • [9] Durvalumab Approved for Unresectable Stage 3 NSCLC After Chemoradiation
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 273 - 273
  • [10] Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC
    Durm, G.
    Althouse, S.
    Sadiq, A.
    Jalal, S.
    Jabbour, S.
    Zon, R.
    Kloecker, G.
    Fisher, W.
    Reckamp, K.
    Kio, E.
    Langdon, R.
    Adesunloye, B.
    Gentzler, R.
    Hanna, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S321 - S321
12345